Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?

• Published in: Molecules (Basel, Switzerland) Vol. 25; no. 9; p. 2026
• Main Authors: Maciejewska, Dominika, Drozd, Arleta, Skonieczna-Żydecka, Karolina, Skórka-Majewicz, Marta, Dec, Karolina, Jakubczyk, Karolina, Pilutin, Anna, Stachowska, Ewa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27.04.2020; MDPI
• Subjects: 13-HODE; 9-HODE; Acids; Animals; biomarkers; Biomarkers - analysis; Biomarkers - blood; Biomarkers - metabolism; Chromatography, Liquid; Dinoprostone - analysis; Dinoprostone - blood; Dinoprostone - metabolism; Disease Models, Animal; Disease Progression; Docosahexaenoic Acids - analysis; Docosahexaenoic Acids - blood; Docosahexaenoic Acids - metabolism; Eicosanoids; Eicosanoids - blood; Eicosanoids - metabolism; Eicosapentaenoic acid; Eicosapentaenoic Acid - analogs & derivatives; Eicosapentaenoic Acid - analysis; Eicosapentaenoic Acid - blood; Eicosapentaenoic Acid - metabolism; Evaluation; Fatty acids; Fatty liver; Health care; Hydroxyeicosatetraenoic Acids - analysis; Hydroxyeicosatetraenoic Acids - blood; Hydroxyeicosatetraenoic Acids - metabolism; Inflammation; Linoleic Acids - analysis; Linoleic Acids - blood; Linoleic Acids - metabolism; Lipid peroxidation; Lipids; Lipoxin A4; Lipoxins - analysis; Lipoxins - blood; Lipoxins - metabolism; Liquid chromatography; Liver; Liver - metabolism; Liver - pathology; Liver diseases; Male; Metabolism; Metabolites; NAFLD; NASH; Non-alcoholic Fatty Liver Disease - blood; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - physiopathology; Prostaglandin E2; Public health; Rats; Rats, Sprague-Dawley; Software; Statistical analysis; Steatosis; Tissues; United Kingdom > UK; eicosanoids; NAFLD; 9-HODE; NASH; biomarkers; 13-HODE
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules25092026

Nonalcoholic fatty liver disease (NAFLD) is becoming a major public health problem worldwide. The study aimed to evaluate the concentration of eicosanoids in serum and liver tissue during steatosis progression and to assess whether eicosanoid change scores may predict liver tissue remodeling. Thirty six eight-week-old male Sprague Dawley rats were enrolled and sacrificed at different stages of NAFLD. Eicosanoid concentrations, namely lipoxin A , hydroxyeicosatetraenoic acids (HETE), hydroxyloctadecadienoic acids (HODE), protectin DX, Maresine1, leucotriene B , prostaglandin E , and resolvin D measurement in serum and liver tissue with Agilent Technologies 1260 liquid chromatography were evaluated. For the liver and serum concentrations of 9-HODE and 13-HODE, the correlations were found to be strong and positive (r > 0.7, < 0.05). Along with NAFLD progression, HODE concentration significantly increased, and change scores were more abundant in the liver. The moderate positive correlation between liver and serum (r = 0.52, < 0.05) was also observed for resolvin E1. The eicosanoid concentration decreased during NAFLD progression, but mostly in serum. There were significant correlations between HETE concentrations in liver and serum, but their associations were relatively low and changes the most in liver tissue. Eicosanoids profile, predominantly 9-HODE and 13-HODE, may serve as a potential biomarker for NAFLD development.